Trial · NCT02364076

Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

NCT02364076, Phase 2, Unknown, Georgetown University; results first posted 2019-12-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma. Trials, record NCT02364076. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02364076

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
NCT number: NCT02364076
Status: Unknown
Phases: Phase 2
Enrollment: 45 participants, actual
Lead sponsor: Georgetown University
Conditions: Thymic Carcinoma, Thymus Neoplasms, Thymus Cancer
Interventions: Pembrolizumab, Epacadostat
First posted: 2015-02-16
Last updated: 2019-12-13
Results first posted: 2019-12-13

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Response Rate	24 months	To measure response of all the participants to the drug at the end of the study.
Secondary	Progression-free Survival	24 months	Time between start of treatment and tumor progression or death
Secondary	Overall Survival	24 months	Time between start of treatment and death
Secondary	Number of Participants With New-Onset Severe Adverse Events	24 months

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Response Rate	24 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Progression-free Survival	24 months	months	MEDIAN
SECONDARY	Overall Survival	24 months	months	MEDIAN
SECONDARY	Number of Participants With New-Onset Severe Adverse Events	24 months	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group7

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Response Rate	Pembrolizumab	Complete Response	1		Participants
Response Rate	Pembrolizumab	Partial response	8		Participants
Response Rate	Pembrolizumab	Stable Disease	21		Participants
Response Rate	Pembrolizumab	Progression	10		Participants
Progression-free Survival	Pembrolizumab		4.2	95% Confidence Interval 2.9 to 10.3	months
Overall Survival	Pembrolizumab		24.9	95% Confidence Interval 15.5 to NA	months
Number of Participants With New-Onset Severe Adverse Events	Pembrolizumab		6		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pembrolizumab and Epacadostat	45
Overall Study	COMPLETED	Pembrolizumab and Epacadostat	40
Overall Study	NOT COMPLETED	Pembrolizumab and Epacadostat	5

Source ClinicalTrials.gov

Adverse events39

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Fatigue	General disorders	Pembrolizumab and Epacadostat	16	40
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Pembrolizumab and Epacadostat	3	40
other	hypothyroidism	Endocrine disorders	Pembrolizumab and Epacadostat	5	40
other	hypokalemia	Metabolism and nutrition disorders	Pembrolizumab and Epacadostat	1	40
other	Elevated alkaline phosphatase	Metabolism and nutrition disorders	Pembrolizumab and Epacadostat	10	40
other	myocarditis	Cardiac disorders	Pembrolizumab and Epacadostat	2	40
other	AST elevation	Metabolism and nutrition disorders	Pembrolizumab and Epacadostat	16	40
other	Flu like	General disorders	Pembrolizumab and Epacadostat	2	40
other	ALT increased	Hepatobiliary disorders	Pembrolizumab and Epacadostat	10	40
other	Diarrhoea	Gastrointestinal disorders	Pembrolizumab and Epacadostat	9	40

1 to 10 of 39Source ClinicalTrials.gov

See all 39 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pembrolizumab and Epacadostat	17	40
Total, other adverse events	Pembrolizumab and Epacadostat	40	40
Total, serious adverse events	Pembrolizumab and Epacadostat	6	40

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
29395863	DERIVED	PubMed
34622229	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02364076

GET https://conductscience.org/api/trials/v1/NCT02364076/events?page=2

API reference For AI assistants